Becton, Dickinson (BDX) said Thursday that it agreed to collaborate with the University of Pennsylvania's Institute for Immunology and Immune Health on deep human immune profiling research and the development of immune-mediated therapies.
The collaboration includes the development of a high-parameter flow cytometry panel that can provide insight into how single cells respond to drugs or disease states, the company said. This panel is expected to support a planned 1,000-patient immune profiling study that is set to start in summer, Becton, Dickinson added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments